Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Women with breast cancer may experience problems with tasks like finding the right words to convey a message or following directions to a destination more than six months after chemotherapy treatment ends, a recent analysis finds. While these verbal and visuospatial issues may be concerning, no other cognitive functions, such as attention, focus, memory or dexterity, were significantly affected after treatment ended.
A re-analysis of data from the NeoALTTO trial found that women whose tumors disappeared after neoadjuvant, or pre-surgery, treatment, were just as likely to have mastectomy as they were to have lumpectomy.
A large study of medical records found that women in their 70s with stage I, estrogen receptor-positive breast cancer who had radiation therapy after lumpectomy were less likely than those who did not to need a later mastectomy.
A comprehensive study of breast tumors at the molecular level — their genetic makeup — has confirmed that breast cancer can be broken into four different types.
Though researchers have known for many years that the four types exist, this is the first study to show from a genetic standpoint how each type is unique. The hope is that this new knowledge may, in the future, lead to treatments that are better tailored to individual types of breast cancer.
LONDON (Reuters) - Breast-cancer screening saves lives even though it also picks up cases in some women that would never have caused them a problem, according to a review published in The Lancet medical journal.
NEW YORK (Reuters Health) - Acupuncture may help relieve fatigue in women who've had breast cancer, a new UK study suggests.
NEW YORK (Reuters Health) - Women about to have breast cancer surgery may want to pay extra attention to the radiation treatment they could be offered afterward.
Updated results from the international EMILIA study show that trastuzumab emtansine (T-DM1), an antibody-drug conjugate, increased both progression-free and overall survival in people with HER2 positive locally advanced and metastatic breast cancer. The new findings also confirm that T-DM1 offers a less toxic treatment option than a standard combination of lapatinib (Tykerb) plus capecitabine (Xeloda), called XL.
NEW YORK (Reuters Health) - Younger women who are thrust into menopause because of breast cancer treatment may get some relief from talk therapy and regular exercise, a new study from the Netherlands suggests.
Seventy-six percent of women with breast cancer report never asking an oncologist or nurse about problems with sex life during or after treatment, despite nearly the same amount believing such conversations important, a recent study showed.